Cargando…

Adherence, exposure and patients’ experiences with the use of erlotinib in non-small cell lung cancer

PURPOSE: Erlotinib is an orally administered tyrosine kinase inhibitor used for treatment of non-small cell lung cancer. Understanding actual use of medication is essential for optimizing treatment conditions. METHODS: In this multicentre prospective observational study, patients starting erlotinib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Timmers, Lonneke, Boons, Christel C. L. M., Moes-ten Hove, J., Smit, Egbert F., van de Ven, Peter M., Aerts, Joachim G., Swart, Eleonora L., Boven, Epie, Hugtenburg, Jacqueline G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2015
Materias:	Original Article – Clinical Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4469769/ https://www.ncbi.nlm.nih.gov/pubmed/25743274 http://dx.doi.org/10.1007/s00432-015-1935-0

Ejemplares similares

The use of erlotinib in daily practice: a study on adherence and patients' experiences
por: Timmers, Lonneke, et al.
Publicado: (2011)

The use of capecitabine in daily practice: a study on adherence and patients’ experiences
por: Timmers, Lonneke, et al.
Publicado: (2012)

Adherence and Patients' Experiences with the Use of Capecitabine in Daily Practice
por: Timmers, Lonneke, et al.
Publicado: (2016)

Study protocol of the RAND-study: a multicenter, prospective cohort study investigating response and adherence to nilotinib treatment in chronic myeloid leukemia
por: Boons, Christel CLM, et al.
Publicado: (2014)

Supporting adherence to oral anticancer agents: clinical practice and clues to improve care provided by physicians, nurse practitioners, nurses and pharmacists
por: Timmers, Lonneke, et al.
Publicado: (2017)

Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib
por: Boons, Christel C. L. M., et al.
Publicado: (2020)

Patient satisfaction with information on oral anticancer agent use
por: Boons, Christel C. L. M., et al.
Publicado: (2017)

Patient experiences and views on pharmaceutical care during adjuvant endocrine therapy for breast cancer: A qualitative study
por: En‐nasery ‐ de Heer, Selma, et al.
Publicado: (2022)

Implementation fidelity of an intervention programme to enhance adherence to antihypertensive medication in Dutch community pharmacies
por: van der Laan, Danielle M., et al.
Publicado: (2019)

Effectiveness of a Patient-Tailored, Pharmacist-Led Intervention Program to Enhance Adherence to Antihypertensive Medication: The CATI Study
por: van der Laan, Danielle M., et al.
Publicado: (2018)

The Cost-Effectiveness of an Intervention Program to Enhance Adherence to Antihypertensive Medication in Comparison With Usual Care in Community Pharmacies
por: Bosmans, Judith E., et al.
Publicado: (2019)

The (cost-)effectiveness of a patient-tailored intervention programme to enhance adherence to antihypertensive medication in community pharmacies: study protocol of a randomised controlled trial
por: van der Laan, Danielle M., et al.
Publicado: (2017)

Food‐effect study of nilotinib in chronic myeloid leukaemia (NiFo study): Enabling dose reduction and relief of treatment burden
por: Boons, Christel C. L. M., et al.
Publicado: (2020)

Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?
por: Lind, Joline S. W., et al.
Publicado: (2010)

Definitions, variants, and causes of nonadherence with medication: a challenge for tailored interventions
por: Hugtenburg, Jacqueline G, et al.
Publicado: (2013)

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

Factors Associated With Nonadherence to Cardiovascular Medications: A Cross-sectional Study
por: van der Laan, Danielle M., et al.
Publicado: (2019)

Radiotherapy and Erlotinib Combined: Review of the Preclinical and Clinical Evidence
por: Mehta, Vivek K.
Publicado: (2012)

Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
por: Zhang, Shu, et al.
Publicado: (2016)

The impact of cardiovascular medication use on patients’ daily lives: a cross-sectional study
por: van der Laan, Danielle M., et al.
Publicado: (2018)

Potential drug interactions and duplicate prescriptions among ambulatory cancer patients: a prevalence study using an advanced screening method
por: van Leeuwen, Roelof WF, et al.
Publicado: (2010)

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials
por: Deng, Wusheng, et al.
Publicado: (2022)

Phase II Trial of Erlotinib during and after Radiotherapy in Children with Newly Diagnosed High-Grade Gliomas
por: Qaddoumi, Ibrahim, et al.
Publicado: (2014)

SYMptom monitoring with Patient-Reported Outcomes using a web application among patients with Lung cancer in the Netherlands (SYMPRO-Lung): study protocol for a stepped-wedge randomised controlled trial
por: Billingy, Nicole E, et al.
Publicado: (2021)

The Role of ARL4C in Erlotinib Resistance: Activation of the Jak2/Stat 5/β-Catenin Signaling Pathway
por: Liao, Jinrong, et al.
Publicado: (2020)

Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma
por: Belderbos, Robert A., et al.
Publicado: (2020)

Type I Collagen Aging Increases Expression and Activation of EGFR and Induces Resistance to Erlotinib in Lung Carcinoma in 3D Matrix Model
por: Sarazin, Thomas, et al.
Publicado: (2020)

Efficacy of erlotinib in NSCLC harboring rare EGFR extracellular domain mutation (T263P) and common mutations: Case report and literature review
por: Wang, Qian, et al.
Publicado: (2022)

Positron Emission Tomography as a Method for Measuring Drug Delivery to Tumors in vivo: The Example of [(11)C]docetaxel
por: van der Veldt, Astrid A. M., et al.
Publicado: (2013)

Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
por: Cantini, Luca, et al.
Publicado: (2020)

Maintained Complete Response and Long-Term Survival in Epidermal Growth Factor Receptor Mutated Metastatic Non-Small Cell Lung Cancer with Erlotinib
por: Alkassis, Samer, et al.
Publicado: (2021)

Prognostic Value of Deep Learning-Mediated Treatment Monitoring in Lung Cancer Patients Receiving Immunotherapy
por: Trebeschi, Stefano, et al.
Publicado: (2021)

Combination Erlotinib-Cisplatin and Atg3-Mediated Autophagy in Erlotinib Resistant Lung Cancer
por: Lee, Jasmine G., et al.
Publicado: (2012)

Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib
por: Melosky, B., et al.
Publicado: (2008)

SRC and MEK Co-inhibition Synergistically Enhances the Anti-tumor Effect in Both Non-small-cell Lung Cancer (NSCLC) and Erlotinib-Resistant NSCLC
por: Yuan, Man, et al.
Publicado: (2019)

Overexpression of Circular RNA circ_0013587 Reverses Erlotinib Resistance in Pancreatic Cancer Cells Through Regulating the miR-1227/E-Cadherin Pathway
por: Xu, Huiting, et al.
Publicado: (2021)

Fibroblast Growth Factor Receptor 1-4 Genetic Aberrations as Clinically Relevant Biomarkers in Squamous Cell Lung Cancer
por: Moes-Sosnowska, Joanna, et al.
Publicado: (2022)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
por: Honeywell, Richard J., et al.
Publicado: (2020)

Factors related to high and low levels of drug adherence according to patients with type 2 diabetes
por: Borgsteede, Sander D., et al.
Publicado: (2011)

Extensive patient-to-patient single nucleus transcriptome heterogeneity in pheochromocytomas and paragangliomas
por: Brazda, Peter, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_benu27g6fop0df1gsc42592m2s